Multiple System Atrophy, Cerebellar Variant (Disorder)
Conditions
Keywords
Multiple System Atrophy, Cerebellar Ataxia, Transcranial Direct Current Stimulation
Brief summary
The aim of study is to investigate most effective site for control the motor coordination using transcranial direct current stimulation in multiple system atrophy with cerebellar feature
Detailed description
Participants receive transcranial direct current stimulation (tDCS) over M1, cerebellar cortex or sham stimulation for 30 minutes. The type of stimulation depends on random assignment. The participants have a 1 week of wash out period between each stimulation. The assessment will be done by International Cooperative Ataxia Rating Scale (ICARS), GAITRITE (CIR Systems Inc., Clifton, New Jersey, USA) and PEDOSCAN (DIERS PEDO, Germany) at baseline and immediately after each treatment.
Interventions
DEVICEtranscranial direct current stimulation
tDCS involves application of very low amplitude direct current via surface scalp electrodes. The applied current modifies the transmembrane neuronal potential and thus influences the level of excitability. Depending on the polarity of active electrodes tDCS can increase or decrease the cortical excitability.
Sponsors
Samsung Medical Center
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
40 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* 1\. Patients who meet the clinical criteria for probable multiple system atrophy with cerebellar features (MDS second consensus statement on the diagnosis of multiple system atrophy) * 2\. Patients aged between 40 and 70 * 3\. Patients who do not have rigidity and bradykinesia * 4\. Patients who have given voluntary consent after understanding the content of the clinical trial
Exclusion criteria
* 1\. Patients with a serious cognitive disorder, behavioral disorder, or mental illness * 2\. Patients have history of seizure, stroke, encephalitis, other degenerative neurological disease * 3\. Patients with a serious medical disease * Patients who concomitantly suffer from severe renal impairment, convulsions, stomach ulcers, moderate or more severe liver disease * Patients with un-controlled high blood pressure or diabetes * 4\. Patients who have taken another investigational products within 4 weeks prior to being enrolled in this clinical trial, or patients who are pregnant or breastfeeding
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change from International Cooperative Ataxia Rating Scale (ICARS) | per session: at baseline and within 30 minutes tDCS treatment completion | The scale is scored out of 100 with 19 items and 4 subscales of postural and gait disturbances, limb ataxia, dysarthria, and oculomotor disorders. Higher scores indicate higher levels of impairment. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change from temporospatial parameters of gait | per session: at baseline and within 30 minutes tDCS treatment completion | Gait parameters measured by GAITRite system |
| Change from posturography | per session: at baseline and within 30 minutes tDCS treatment completion | Posturography measured by Pedoscan system |
Countries
South Korea
Contacts
Primary ContactJinyoung Youn
Backup ContactJong Hyeon Ahn
Outcome results
None listed